Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

(2020) Shukui Qin et al.   LANCET ONCOLOGY

Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial

(2020) Feng Wang et al.   Journal of Hematology & Oncology

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

(2020) Jing Huang et al.   LANCET ONCOLOGY

Immuno-oncology for esophageal cancer

(2020) Shun Yamamoto et al.   Future Oncology

LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study

(2020) K. Kato et al.   ANNALS OF ONCOLOGY

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

(2020) Takashi Kojima et al.   JOURNAL OF CLINICAL ONCOLOGY

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

(2020) Caicun Zhou et al.   Lancet Respiratory Medicine

A single-arm, multicenter, phase 2 study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma

(2019) Yuqin Song et al.   CLINICAL CANCER RESEARCH

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

(2019) Ken Kato et al.   LANCET ONCOLOGY

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

(2019) Barbara Burtness et al.   LANCET

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

(2018) Karina Kulangara et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

(2018) Wenfeng Fang et al.   LANCET ONCOLOGY

Unknown

(2018)   CA-A CANCER JOURNAL FOR CLINICIANS

Oesophageal carcinoma

(2013) Arjun Pennathur et al.   LANCET

Assessing the fit of parametric cure models

(2012) E. P. Wileyto et al.   BIOSTATISTICS

Epidemiologic differences in esophageal cancer between Asian and Western populations

(2012) Han-Ze Zhang et al.   Chinese Journal of Cancer

A Phase II Trial of Paclitaxel and Cisplatin in Patients With Advanced Squamous-Cell Carcinoma of the Esophagus

(2009) Xiaodong Zhang et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials

(2008) Kim Cocks et al.   EUROPEAN JOURNAL OF CANCER